Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults
| Autor: | Eric W Hall, Mark K Weng, Aaron M Harris, Sarah Schillie, Noele P Nelson, Ismael R Ortega-Sanchez, Elizabeth Rosenthal, Patrick S Sullivan, Ben Lopman, Jeb Jones, Heather Bradley, Eli S Rosenberg |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | The Journal of Infectious Diseases. 226:1041-1051 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiac088 |
| Popis: | Background Although effective against hepatitis B virus (HBV) infection, hepatitis B (HepB) vaccination is only recommended for infants, children, and adults at higher risk. We conducted an economic evaluation of universal HepB vaccination among US adults. Methods Using a decision analytic model with Markov disease progression, we compared current vaccination recommendations (baseline) with either 3-dose or 2-dose universal HepB vaccination (intervention strategies). In simulated modeling of 1 million adults distributed by age and risk groups, we quantified health benefits (quality-adjusted life years, QALYs) and costs for each strategy. Multivariable probabilistic sensitivity analyses identified key inputs. All costs reported in 2019 US dollars. Results With incremental base-case vaccination coverage up to 50% among persons at lower risk and 0% increment among persons at higher risk, each of 2 intervention strategies averted nearly one-quarter of acute HBV infections (3-dose strategy, 24.8%; 2-dose strategy, 24.6%). Societal incremental cost per QALY gained of $152 722 (interquartile range, $119 113–$235 086) and $155 429 (interquartile range, $120 302–$242 226) were estimated for 3-dose and 2-dose strategies, respectively. Risk of acute HBV infection showed the strongest influence. Conclusions Universal adult vaccination against HBV may be an appropriate strategy for reducing HBV incidence and improving resulting health outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|